Open Access Open Access  Restricted Access Subscription or Fee Access

Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: A randomized, phase IIIb study

Gary J. Vorsanger, PhD, MD, Angela M. Klopfer, BS, Jim Xiang, PhD, Carmela J. Benson, MS, Bruce L. Moskovitz, MD, Norman R. Rosenthal, MD

Abstract


Objective: Arthroscopic shoulder surgery can result in substantial postoperative pain. This study evaluated the efficacy and safety of tapentadol immediate release (IR) or oxycodone IR in this setting for the treatment of acute pain.

Design: Subjects received tapentadol IR 50 or 100 mg or oxycodone IR 5 or 10 mg every 4-6 hours as needed for pain up to 7 days after arthroscopic shoulder surgery. Twice daily, subjects recorded pain intensity from 0 (no pain) to 10 (pain as bad as you can imagine) and pain relief from 0 (none) to 5 (complete). Final assessments included patient and clinician global impression of change and subject satisfaction with treatment. The primary efficacy endpoint was the sum of pain intensity differences (SPID) over 3 days.

Results: Of 378 subjects (192 tapentadol IR, 186 oxycodone IR) who took study medication, 312 (158 tapentadol IR, 154 oxycodone IR) had pain intensity 4 before the first dose and were evaluated for efficacy. Mean SPID scores over 3 days were 32.1 and 41.1 in the tapentadol IR and oxycodone IR groups, respectively (least-squares mean difference [95% confidence interval], 9.0 [-18.9, 36.9]; p = 0.527). Secondary analyses of pain intensity, pain relief, and subject satisfaction were similar between groups. Subjects and clinicians reported significantly better global impression of change for tapentadol IR. Adverse events were consistent with established safety profiles for IR opioids.

Conclusions: Tapentadol IR and oxycodone IR had similar efficacy for pain after arthroscopic shoulder surgery, but subjects and clinicians reported greater overall improvement with tapentadol IR.


Keywords


tapentadol, oxycodone, postoperative pain, shoulder surgery

Full Text:

PDF

References


Mahîrogullari M, Özkan H, Akyüz M, et al.: Comparison between the results of open and arthroscopic repair of isolated traumatic anterior instability of the shoulder. Acta Orthop Traumatol Turc. 2010; 44: 180-185.

Cho CH, Song KS, Jung GH, et al.: Early postoperative outcomes between arthroscopic and mini-open repair for rotator cuff tears. Orthopedics. 2012; 35: e1347-e1352.

Wilson AT, Nicholson E, Burton L, et al.: Analgesia for day-case shoulder surgery. Br J Anaesth. 2004; 92: 414-415.

Fredrickson MJ, Krishnan S, Chen CY: Postoperative analgesia for shoulder surgery: A critical appraisal and review of current techniques. Anaesthesia. 2010; 65: 608-624.

Tzschentke TM, Christoph T, Kogel B, et al.: (_)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): A novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323: 265-276.

Kleinert R, Lange C, Steup A, et al.: Single dose analgesic efficacy of tapentadol in postsurgical dental pain: The results of a randomized, double-blind, placebo-controlled study. Anesth Analg. 2008; 107: 2048-2055.

Stegmann JU, Weber H, Steup A, et al.: The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin. 2008; 24: 3185-3196.

Daniels S, Casson E, Stegmann JU, et al.: A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin. 2009; 25: 1551-1561.

Daniels SE, Upmalis D, Okamoto A, et al.: A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin. 2009; 25: 765-776.

Reisman RM, Shenoy PJ, Atherly AJ, et al.: Prescription opioid usage and abuse relationships: An evaluation of state prescription drug monitoring program efficacy. Subst Abuse Res Treat. 2009; 3: 41-51.

Anastassopoulos KP, Chow W, Ackerman SJ, et al.: Oxycodone-related side effects: Impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. J Opioid Manag. 2011; 7: 203-215.

Hartrick C, Van Hove I, Stegmann JU, et al.: Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009; 31: 260-271.

Hale M, Upmalis D, Okamoto A, et al.: Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: A randomized, double-blind study. Curr Med Res Opin. 2009; 25: 1095-1104.

Dworkin RH, Turk DC, Wyrwich KW, et al.: Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008; 9: 105-121.

Turk DC, Dworkin RH, Allen RR, et al.: Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106:337-345.




DOI: https://doi.org/10.5055/jom.2013.0170

Refbacks

  • There are currently no refbacks.